Anagrelide controlled release - Galena Biopharma

Drug Profile

Anagrelide controlled release - Galena Biopharma

Alternative Names: Anagrelide CR - Galena Biopharma; CR anagrelide - Galena Biopharma; GALE-401

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mills Pharmaceuticals
  • Developer Galena Biopharma
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Essential thrombocythaemia
  • No development reported Chronic myeloid leukaemia; Myelofibrosis; Polycythaemia vera

Most Recent Events

  • 12 Jul 2017 Anagrelide controlled release - Galena Biopharma is available for licensing as of 12 Jul 2017.
  • 11 Mar 2017 Anagrelide controlled release is still at phase II development stage for Essential thrombocythaemia in USA (PO)
  • 10 Mar 2017 No recent reports of development identified - Phase-II for Polycythaemia vera, Myelofibrosis and Chronic myeloid leukaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top